It makes the difficult middle steps of other companies' drug molecules — and it has just found a second life selling into semiconductors and batteries. Acutaas Chemicals, called Ami Organics until last year, makes advanced pharmaceutical intermediates: the complex fragments an innovator needs on the way to a finished drug. That business did ₹292.7 crore in the June 2026 quarter, up 76.5%, and is now 89% of the company. A second segment, specialty chemicals, did ₹37 crore. The full year to March 2026: revenue ₹1,339 crore, up 33%, and profit ₹356 crore, up 124%. EBITDA margin of 35.9% against 23.0% the year before. Return on capital employed of 32.3%. Those are the best figures of any specialty chemicals company covered here, and the reason is mix rather than scale. Acutaas is a sixth of Deepak Nitrite's revenue and earns nearly three times the margin, because it sells difficulty rather than volume.
On the measure that decides a contract chemistry business — what customers ask you to make next — the pipeline is full. On the one that decides this year, management has given a number and can be held to it. For a company selling intermediates to innovators, the measures are the rate of new enquiries and how far up the value chain the work sits. Management reports healthy request-for-proposal activity across both its contract development work and new chemical entities, with the research team "working around the clock" against that pipeline. The second measure is the one worth marking in a calendar: the chairman committed publicly to 25% revenue growth for the full year with stable margins. The June quarter grew 59%, so the guidance implies a deliberate slowing — an unusually checkable statement, and this page will check it. Where the company is less forthcoming is capacity utilisation, which it does not report.
There is effectively none, and there is more cash than debt. Borrowings at March 2026 were ₹35.6 crore against a net worth of ₹1,654 crore — a debt-to-equity ratio of 0.02. Cash was ₹225 crore, so the company is net cash by ₹189 crore. The chief financial officer put net cash at ₹314 crore by 30 June. Borrowings did rise, from ₹12.9 crore, but the numbers are small enough that the change means very little. A company spending ₹56 crore on capital projects in a single quarter and still carrying more cash than debt is funding growth from what it earns. Nothing here constrains anything.
Growing fast, and profit is growing nearly four times as fast. Year to March 2026: revenue ₹1,339 crore, up 33%. Profit ₹356 crore, up 124%. EBITDA margin went from 23.0% to 35.9%; net margin from 15.8% to 26.6%. This is not a one-year event. Revenue has compounded at 31% over five years and profit at 46%. The margin expansion is the newer part, and it comes from mix — the higher-margin pharmaceutical intermediates business growing while low-margin commodity chemicals are deliberately phased out. The June 2026 quarter continued it: revenue ₹329.7 crore up 59%, EBITDA ₹113.1 crore up 122%, margin 34.3% against 24.6%. One honest note on that quarter: profit rose 70% while EBITDA rose 122%, because other income was lower than a year earlier. The operating business did better than the profit line suggests.
A third more revenue, and more than double the profit. Year to March 2026: revenue ₹1,339 crore against ₹1,007 crore. Profit ₹356 crore against ₹159 crore. Earnings per share of ₹43.50. The longer record is consistent rather than lumpy: revenue compounding at 29% over three years and 31% over five; profit at 62% and 46%. June 2026 quarter, by segment: advanced pharmaceutical intermediates ₹292.7 crore, up 76.5%; specialty chemicals ₹37 crore, down 10.6%. The decline is intentional — commodity products are being retired in favour of higher-margin ones.
Its own plants, and a lot of them at once. No acquisitions. Gross block rose 31%, from ₹570 crore to ₹745 crore, with a further ₹332 crore in capital work in progress — nearly half the completed asset base again. Investing outflow for the year was ₹266 crore. Capital spending in the June quarter alone was ₹56 crore: ₹41 crore at the ACL site, mostly the battery chemicals project at Jhagadia, plus a pilot plant at Sachin, and ₹15 crore at the Indichem site. Management has flagged further spending on a new research centre and land for expansion, not yet finalised. The battery chemicals plant completed its trial run during the quarter and started commercial supply — so this is capital that has begun converting into revenue rather than sitting in progress.
Improving sharply, and the company is engineering it on purpose. EBITDA margin for the year to March 2026 was 35.9% against 23.0% — nearly thirteen points. Net margin 26.6% against 15.8%. Gross margin 55.6%. The June quarter shows the mechanism. Gross margin expanded 466 basis points to 57.9%, which the chief financial officer attributed directly to a higher contribution from pharmaceutical intermediates. EBITDA margin expanded 973 basis points to 34.3% — gross margin plus operating leverage. Underneath is a deliberate choice: commodity chemicals are being phased out and replaced with higher-margin products. Specialty chemicals revenue fell 10.6% in the quarter as a result, and management warns of a transition gap while plants are reconfigured. The margin is being bought with revenue, knowingly.
Better than anything else covered here. Return on capital employed was 32.3% for the year to March 2026, up from 20.1%. Return on equity 21.5%, up from 12.1%. The gap between those two is worth understanding: return on equity is lower because the company holds a great deal of cash and almost no debt, so equity funds assets that earn nothing. That is a conservative balance sheet dragging a ratio, not a business problem. Capital employed is ₹1,689 crore, of which ₹332 crore is still under construction. The 32.3% is being earned on a base that has not finished being built.
Cash roughly matches profit, and collections are slow but improving. Operating cash flow over three years came to ₹536 crore against ₹558 crore of profit — a ratio of 0.96. For the year alone, ₹292 crore against ₹356 crore of profit, up sharply from ₹118 crore the year before. Collections are the weaker part. Debtor days stand at 99, down from 105, and inventory at 63 days. The chief financial officer put working capital at 99 days in the June quarter against 91 in the March quarter — better debtors and creditors offset by higher inventory. Ninety-nine days is long against Deepak Nitrite's 70, and reflects who the customers are: innovator pharmaceutical companies pay on their own schedule.
Acutaas has not yet published its annual report for the year to March 2026, so most of this one waits. Naresh Patel is executive chairman and managing director — both roles in one person. Abhishek Patel is president of strategy and Bhavin Shah chief financial officer. Beyond that — the composition of the board, the auditors and their opinion, litigation, and dealings with companies connected to the owners — the answers come from the annual report, and it is not out. They will be written when it is. What can be answered without it, the ownership and pledge position, is below.
It sells the same kind of difficulty as the CDMO companies covered here, and it has just walked into two industries none of them are in. The pharmaceutical intermediates business puts Acutaas alongside Divi's Laboratories, Laurus Labs, Neuland and Sai Life — all covered on this site — making molecules to order for innovators. At ₹1,339 crore of annual revenue it is much the smallest of that group, and at 35.9% EBITDA margin the most profitable of it. What none of them have is the second business. Acutaas makes materials that go into semiconductors and, since this quarter, battery chemicals. Management's argument is that AI demand is pulling memory chip production up against tight supply, and that this is structural rather than a cycle. That is either a genuinely different company from its peers or a small segment with a good story attached. On ₹37 crore of quarterly specialty revenue, the evidence does not yet decide it.
In pharmaceutical intermediates, four companies covered on this site. In what it is becoming, almost nobody in India. For the business that is 89% of revenue, the comparison set is Divi's Laboratories, Laurus Labs, Neuland Laboratories and Sai Life Sciences — all covered here, all selling contract chemistry to global innovators. Acutaas is far the smallest: ₹1,339 crore of annual revenue against Divi's ₹10,560 crore, Laurus's ₹6,813 crore, Sai Life's ₹2,192 crore and Neuland's ₹2,023 crore. It is also the most profitable of the five, at a 35.9% EBITDA margin against Divi's 32.6% and Laurus's 26.2%. Within specialty chemicals it meets Navin Fluorine and Deepak Nitrite, also covered here, but barely — that segment is ₹37 crore a quarter against Navin's ₹325 crore and Deepak's ₹804 crore of intermediates. The area where it has few Indian rivals is electronic-grade materials for semiconductors. Navin Fluorine is building toward the same end market from fluorine chemistry and has said so explicitly. Neither is there yet, which makes this a race rather than a competition.
Helping: three separate demand stories arriving at once. Hurting: a deliberate revenue hole, and raw materials that come through the Gulf. Helping. Contract development work is growing strongly and the enquiry pipeline is healthy. Battery chemicals moved from trial to commercial supply during the quarter, into what management calls unprecedented demand and tight global supply. And the semiconductor materials business is being pulled by memory chip demand, which is being pulled by AI. Hurting, and self-inflicted: commodity chemicals are being retired on purpose, which is why the specialty segment shrank 10.6% while everything else grew. Management warns of a transition gap between the old product going and the new one ramping, and says minor capital spending is needed to reconfigure plants. Hurting, and not self-inflicted: the chairman opened the call by describing a turbulent start to the year driven by geopolitical tension in the Gulf, with the team working to secure raw material availability. That exposure has not gone away. And the one to hold them to: 25% full-year revenue growth with stable margins, stated publicly, against 59% growth in the first quarter.
A long-term grower with a lumpy revenue line, which is not the same as a stable one. Contract chemistry for pharmaceutical innovators grows with global drug pipelines and with the shift of manufacturing out of China — a decade-long move rather than a cycle. But revenue arrives in campaigns, and a molecule that fails a trial takes its revenue with it. The two newer end markets are different again. Semiconductor materials follow the capital spending of a handful of chipmakers, which is among the most cyclical industries there is wrapped around one of the most structural. Battery chemicals follow electrification. None of these is boom-and-bust in the way commodity chemicals are, because none of them is priced off a published spread. All of them can disappoint for years at a time.
It is priced as the best company in its sector, which for the moment it is. At ₹3,198.20 on 17 August 2026 the company is worth ₹26,193 crore — 73.5 times the year to March 2026's earnings, 15.8 times book, and 19.6 times sales. Nineteen times sales is the number to sit with. That is a multiple normally paid for software, and it is being paid for a chemicals company earning 35.9% margins with a 31% five-year growth record. The bull case is that the margin and the growth are both real and both improving, and the price-to-earnings-growth ratio of 1.2 says the multiple is not absurd against the growth. The bear case is that management has guided to 25% growth, not 59%, and that a company this expensive has no room to miss.
Expensive by every measure, and the dearest of the three specialty chemicals companies covered here. On 17 August 2026 the share was ₹3,198.20 — 73.5 times earnings of ₹43.50 per share, 15.8 times a book value of ₹202, and 19.6 times sales. Earnings yield 1.4%. Against the others in its sector covered here: Acutaas at 73.5 times, Navin Fluorine at 63, Deepak Nitrite at 44. Acutaas is also the fastest-growing and the highest-margin of the three, so the ranking is not arbitrary — but it is priced for all of that to continue. The share is 13.4% below its 52-week high of ₹3,694.80, having risen 140% over the year from a low of ₹1,317.80.
Foreign funds have been buying steadily, and domestic ones have been letting them. Institutions held 41.17% at 30 June 2026, up 1.85 points over four quarters. The movement is entirely foreign: overseas institutions went from 16.94% to 21.61%, while domestic institutions fell from 22.38% to 19.56%. Mutual funds hold 14.17%. Public shareholding fell from 28.01% to 26.16% — but the number of shareholders rose 4.7%, from 119,890 to 125,569. More individual holders, each owning less. Foreign institutions at 21.6% is high for a company of this size, and the direction has been consistent rather than a single quarter's block purchase.
Foreign institutions own more than a fifth of it, and no single name dominates the register. Foreign institutional holders account for 21.61% at 30 June 2026 and mutual funds 14.17%, against a promoter holding of 32.66%. Institutions in total hold 41.17% — more than the founders. The distinguishing feature against the other specialty chemicals companies covered here is where the money comes from. Deepak Nitrite's register is entirely domestic; Navin Fluorine's includes Norway's sovereign fund and Vanguard. Acutaas sits closer to Navin, with foreign ownership that has risen in each of the last four quarters.
A token dividend, no new shares, and no need for either. The dividend for the year to March 2026 was ₹2.50 per share — a payout of 5.7% of profit and a yield of under 0.1%. Nominal, and appropriate for a company putting ₹266 crore a year into plants. No meaningful issuance: dilution over the year was zero and the share count has been 8.19 crore throughout. Employee options account for 0.38%, with 311,373 outstanding. Over five years the share count has grown 30%, which is history rather than current practice. No buyback. With net cash of ₹189 crore at year end and ₹314 crore by June, the company has the means and is choosing to spend it on capacity instead.
Loading…